ObsEva SA

OTCPK:OBSE.F Stok Raporu

Piyasa değeri: US$11.7k

ObsEva Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda ObsEva için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Biotechs kazanç büyümesi25.3%
Gelir büyüme oranın/a
Gelecekteki özkaynak getirisin/a
Analist kapsamı

None

Son güncellemen/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Seeking Alpha • Aug 22

ObsEva stock dips on Nasdaq non-compliance notice

ObsEva SA (NASDAQ:OBSV) received a notice from Nasdaq for failing to comply with the rule of maintaining a minimum of $10M in stockholders' equity for continued listing on the exchange. The company had disclosed in a SEC filing that as of June 30, it had shareholders' equity of ~$2.10M. ObsEva has until Aug. 29 to submit a plan to regain compliance after Nasdaq decided to provide a shortened response time to the company. The company said it intends to submit plan by the date. On July 27, ObsEva stock fell ~78% on plans to restructure following setback for uterine fibroids drug. Earlier in August, the company said it was retiring $31M in debt and had announced $11M debt refinancing. OBSV -4.13% to $0.23 premarket Aug. 22
Seeking Alpha • Aug 01

ObsEva to retire $31M in debt and announces $11M debt refinancing

ObsEva (NASDAQ:OBSV) announced the early retirement of $31M in debt partially owed to certain funds and accounts managed by JGB Management post its securities purchase agreement. The company has also entered into an amendment and forbearance agreement with respect to the outstanding debt held by JGB. Under agreement terms, ObsEva and JGB agreed to apply the $31M cash earlier held as collateral in a control account against the outstanding convertible notes on a pro rata basis, with JGB waiving a 25% prepayment penalty on the early debt retirement. JGB has agreed to forbear for a period of up to three months from enforcing any rights or remedies under the notes. In exchange, $1.5M was added to the outstanding principal balance under the notes, leading to ~$11M of convertible notes outstanding, and the conversion price of the notes was adjusted to a conversion price of $0.26/share. Shares trading 1.6% higher premarket.
Seeking Alpha • Jul 05

ObsEva: Ignored, But Long-Term Prospects Exist On Recent Progress

Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the European Union. Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the United Kingdom. PDUFA date for potential FDA approval of Yselty for the treatment of women with uterine fibroids set for September 13, 2022. Trial results from the phase 3 EDELWEISS 3 study and long-term extension study for endometriosis are expected 2nd half of 2022; Post-treatment follow-up results from extension study expected early 2023. ObsEva SA (OBSV) is a great long-term biotech to own. The reason why I state that is because despite having received regulatory approval in two territories for linzagolix (marketed as Yselty) for the treatment of women with uterine fibroids, the stock still trades at a very low share price. It received approval of this drug for the treatment of this patient population for the European Union and for the United Kingdom. I believe there is long-term potential just based on these approvals. However, there is an ability to further expand the reach of Yselty to the United States. That's because there is a PDUFA date set for September 13, 2022, and that is when the FDA will decide if this drug should be approved for the very same patient population for use in the United States. I believe that the FDA approval may carry more weight compared to the other two regulatory approvals. Not only that, but the biotech won't have to attempt to sell the drug on its own. Instead, it has already been able to establish two partners for specific territories. It established a partnership for Theramex to sell the drug outside of the U.S., Canada, and Asia. The other partnership that was established was with Syneos Health to sell the drug within the United States upon regulatory approval. It is developing Yselty (linzagolix) for another large market indication which is endometriosis as well. With a few regulatory approvals for Yselty, plus another possible one on the way in Q3 of 2022, these are the reasons why I believe that ObsEva is a great long-term biotech to look into. Two Regulatory Approvals With A Third One Being Possible As I noted directly above, ObsEva received regulatory approvals of Yselty for the treatment of women with uterine fibroids in two territories. Uterine fibroids are benign tumors that end up forming in the uterus (womb) of a woman. When I state the term "benign," that means non-cancerous. The thing is that a majority of the time there are no symptoms. However, in certain cases, they can cause severe pain for the patient. There are several symptoms that uterine fibroids can cause, which are: Heavy Menstrual bleeding Prolonged periods Pelvic pain Cramping Urge to urinate One immediate item to point out is that Yselty was explored in uterine fibroid patients with heavy menstrual bleeding. Thus, heavy menstrual bleeding ((HMB)) is one of the symptoms involved with this disease. Some ways to treat this disease are surgeries and medications. Surgeries may involve attempting to go in and remove the uterine fibroids if successful. The other option involves medications. There are two types of medications: SERMs (Selective estrogen receptor modulators) - work by changing estrogen levels in the body and holds the ability to shrink fibroids without causing menopause symptoms GnRH agonist - GnRH is a type of hormone that a person's body makes naturally. These agonist drugs act as a counter to the production of the GnRH hormone. Thus, in turn it is able to shrink fibroids and sometimes can even reduce anemia as well There are many other additional types of surgeries as well, like cutting off the blood supply to kill the fibroid off. The thing is that the uterine fibroids market is a large one. Well, it only treats women and it is just benign fibroids that are being formed in the uterus. Yes, but believe it or not it is indeed a major problem. Just in the United States alone, it is expected that the uterine fibroids treatment market is estimated to be worth $298.5 million by the end of 2027. One of the first regulatory approvals was achieved back on June 22, 2022, from the European Commission ((EC)). This approval was followed by a positive opinion from the Committee Medicinal Products for Human Use of the European Medicines Agency back in April of 2022. Then, the biotech was able to receive UK Medicines and Healthcare Products Regulatory Agency ((MHRA)) approval of Yselty for this very same patient population. The reason why Yselty was approved was because of positive results from the two phase 3 PRIMROSE studies that were done. It was noted from 24 weeks that there were huge response rates. The breakdown of such response rates is as follows: A responder rate of 84.5% in women who received 200 mg linzagolix with hormonal add back therapy ((ABT)) A responder rate of 56.5% in women who received 100 mg of linzagolix without ABT These two response rates, plus safety profile of the drug, is what allowed for these regulatory approvals. However, where I believe ObsEva may have a competitive advantage is that Yselty is the first drug approved for this specific patient population that gives women the option to be treated without the need for hormone therapy. The need for a drug like Yselty now is to help a woman either delay or avoid the need for surgery altogether. There is potential to expand regulatory approval of Yselty to the United States with the upcoming FDA decision in the 2nd half of 2022. A Prescription Drug User Fee Act ((PDUFA)) date has been established with an action date of September 13, 2022. Agreement has been made in partnership with Theramex to sell Yselty outside of the U.S., Canada and Asia. Another agreement had been made with Syneos Health to sell the drug in the United States upon regulatory approval. Financials According to the 6-K SEC Filing, ObsEva had cash and cash equivalents of $57.6 million as of March 31, 2022. It has been able to raise cash through several different methods over the years. It raised about $5.7 million of net cash in Q1 of 2022 using its at-the-market offering program. Then, made $8.3 million in proceeds from its securities purchase agreement with JGB Management. Speaking of which, this JGB Securities Purchase Agreement is structured to provide about $135 million in borrowing capacity in nine tranches. The first and second tranche were achieved, October 2021 and then January 2022 respectively.

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak ObsEva yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

OTCPK:OBSE.F - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
6/30/2023208-8-2N/A
3/31/202320-21-16-10N/A
12/31/202220-30-23-23N/A
9/30/20224-77-38-44N/A
6/30/202222-58-31-36N/A
3/31/2022N/A-50-36-64N/A
12/31/202122-53-50-50N/A
9/30/2021N/A-57-57-80N/A
6/30/2021N/A-82-77-77N/A
3/31/2021N/A-81-77-77N/A
12/31/2020N/A-83-71-71N/A
9/30/2020N/A-85-72-72N/A
6/30/2020N/A-88-89-84N/A
3/31/2020N/A-105-90-85N/A
12/31/2019N/A-109-96-91N/A
9/30/2019N/A-108-90-85N/A
6/30/2019N/A-99-73-73N/A
3/31/20190-83-70-70N/A
12/31/2018N/A-77-64-64N/A
9/30/20180-74-61-60N/A
6/30/20180-72-59-59N/A
3/31/20180-71-65-60N/A
12/31/2017N/A-67-61-56N/A
9/30/20170-61-59-54N/A
6/30/2017N/A-52-52-47N/A
3/31/20170-41N/A-34N/A
12/31/20160-30N/A-29N/A
9/30/20160-26N/A-19N/A
6/30/20160-21N/A-17N/A
3/31/20160-20N/A-15N/A
12/31/20150-20N/A-14N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: OBSE.F 'un tahmini kazanç büyümesinin tasarruf oranının ( 3.5% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: OBSE.F 'un kazançlarının US pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: OBSE.F şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: OBSE.F şirketinin gelirinin US pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: OBSE.F şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: OBSE.F 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/22 21:47
Gün Sonu Hisse Fiyatı2026/05/22 00:00
Kazançlar2023/06/30
Yıllık Kazançlar2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

ObsEva SA 9 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Nathan WeinsteinAegis Capital Corporation
Mayur SomaiyaBMO Capital Markets Equity Research
Edward NashCanaccord Genuity